Serological responses to COVID-19 Comirnaty booster vaccine, London, United Kingdom, September to December 2021

Georgina Ireland; Heather Whitaker; Shamez N. Ladhani; Frances Baawuah; Sathyvani Subbarao; Ezra Linley; Lenesha Warrener; Michelle O'Brien; Corinne Whillock; Oliver Martin; Paul Moss; Mary E. Ramsay; Gayatri Amirthalingam; Kevin E. Brown

doi:10.2807/1560-7917.ES.2022.27.1.2101114

Serological responses to COVID-19 Comirnaty booster vaccine, London, United Kingdom, September to December 2021

Georgina Ireland, Heather Whitaker, Shamez N. Ladhani, Frances Baawuah, Sathyvani Subbarao, Ezra Linley, Lenesha Warrener, Michelle O'Brien, Corinne Whillock, Oliver Martin, Paul Moss, Mary E. Ramsay, Gayatri Amirthalingam, Kevin E. Brown

UK Health Security Agency

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

24 Downloads (Pure)

Abstract

Serum samples were collected pre- and post-booster vaccination with Comirnaty in 626 participants (aged ≥50 years) who had received two Comirnaty doses<30 days apart, two Comirnaty doses≥30 days apart or two Vaxzevria doses≥30 days apart. Irrespective of primary vaccine type or schedule, spike antibody GMTs peaked 2–4 weeks after second dose, fell significantly≤38 weeks later and rose above primary immunisation GMTs 2–4 weeks post-booster. Higher post-booster responses were observed with a longer interval between primary immunisation and boosting.

Original language	English
Article number	2101114
Number of pages	7
Journal	Eurosurveillance
Volume	27
Issue number	1
DOIs	https://doi.org/10.2807/1560-7917.ES.2022.27.1.2101114
Publication status	Published - 6 Jan 2022

Bibliographical note

Funding Information: : This surveillance was funded by PHE now UK Health
Security Agency (UKHSA).

Open Access: This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence and indicate if changes were made.

Publisher Copyright: This article is copyright of the authors or their affiliated institutions, 2022.

Citation: Ireland Georgina, Whitaker Heather, Ladhani Shamez N, Baawuah Frances, Subbarao Sathyvani, Linley Ezra, Warrener Lenesha, O’Brien Michelle, Whillock Corinne, Martin Oliver, Moss Paul, Ramsay Mary E, Amirthalingam Gayatri, Brown Kevin E. Serological responses to COVID-19 Comirnaty booster vaccine, London, United Kingdom, September to December 2021. Euro Surveill. 2022;27(1):pii=2101114.

DOI: https://doi.org/10.2807/1560-7917.ES.2022.27.1.2101114

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2807/1560-7917.ES.2022.27.1.2101114Licence: CC BY

Ireland2022SerologicalResponsesToCOVID-19ComirnatyBoosterVaccineLondonUnitedKingdomEuroSurveillFinal published version, 202 KBLicence: CC BY

Cite this

Ireland, G., Whitaker, H., Ladhani, S. N., Baawuah, F., Subbarao, S., Linley, E., Warrener, L., O'Brien, M., Whillock, C., Martin, O., Moss, P., Ramsay, M. E., Amirthalingam, G., & Brown, K. E. (2022). Serological responses to COVID-19 Comirnaty booster vaccine, London, United Kingdom, September to December 2021. Eurosurveillance, 27(1), Article 2101114. https://doi.org/10.2807/1560-7917.ES.2022.27.1.2101114

@article{246c2b8801c042a4b0268e945dceea56,

title = "Serological responses to COVID-19 Comirnaty booster vaccine, London, United Kingdom, September to December 2021",

abstract = "Serum samples were collected pre- and post-booster vaccination with Comirnaty in 626 participants (aged ≥50 years) who had received two Comirnaty doses<30 days apart, two Comirnaty doses≥30 days apart or two Vaxzevria doses≥30 days apart. Irrespective of primary vaccine type or schedule, spike antibody GMTs peaked 2–4 weeks after second dose, fell significantly≤38 weeks later and rose above primary immunisation GMTs 2–4 weeks post-booster. Higher post-booster responses were observed with a longer interval between primary immunisation and boosting.",

author = "Georgina Ireland and Heather Whitaker and Ladhani, {Shamez N.} and Frances Baawuah and Sathyvani Subbarao and Ezra Linley and Lenesha Warrener and Michelle O'Brien and Corinne Whillock and Oliver Martin and Paul Moss and Ramsay, {Mary E.} and Gayatri Amirthalingam and Brown, {Kevin E.}",

note = "Funding Information: : This surveillance was funded by PHE now UK Health Security Agency (UKHSA). Open Access: This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence and indicate if changes were made. Publisher Copyright: This article is copyright of the authors or their affiliated institutions, 2022. Citation: Ireland Georgina, Whitaker Heather, Ladhani Shamez N, Baawuah Frances, Subbarao Sathyvani, Linley Ezra, Warrener Lenesha, O{\textquoteright}Brien Michelle, Whillock Corinne, Martin Oliver, Moss Paul, Ramsay Mary E, Amirthalingam Gayatri, Brown Kevin E. Serological responses to COVID-19 Comirnaty booster vaccine, London, United Kingdom, September to December 2021. Euro Surveill. 2022;27(1):pii=2101114. DOI: https://doi.org/10.2807/1560-7917.ES.2022.27.1.2101114",

year = "2022",

month = jan,

day = "6",

doi = "10.2807/1560-7917.ES.2022.27.1.2101114",

language = "English",

volume = "27",

journal = "Eurosurveillance",

issn = "1025-496X",

publisher = "European Centre for Disease Prevention and Control (ECDC)",

number = "1",

}

Ireland, G, Whitaker, H , Ladhani, SN, Baawuah, F, Subbarao, S, Linley, E , Warrener, L, O'Brien, M, Whillock, C, Martin, O, Moss, P, Ramsay, ME , Amirthalingam, G & Brown, KE 2022, 'Serological responses to COVID-19 Comirnaty booster vaccine, London, United Kingdom, September to December 2021', Eurosurveillance, vol. 27, no. 1, 2101114. https://doi.org/10.2807/1560-7917.ES.2022.27.1.2101114

TY - JOUR

T1 - Serological responses to COVID-19 Comirnaty booster vaccine, London, United Kingdom, September to December 2021

AU - Ireland, Georgina

AU - Whitaker, Heather

AU - Ladhani, Shamez N.

AU - Baawuah, Frances

AU - Subbarao, Sathyvani

AU - Linley, Ezra

AU - Warrener, Lenesha

AU - O'Brien, Michelle

AU - Whillock, Corinne

AU - Martin, Oliver

AU - Moss, Paul

AU - Ramsay, Mary E.

AU - Amirthalingam, Gayatri

AU - Brown, Kevin E.

N1 - Funding Information: : This surveillance was funded by PHE now UK Health Security Agency (UKHSA). Open Access: This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence and indicate if changes were made. Publisher Copyright: This article is copyright of the authors or their affiliated institutions, 2022. Citation: Ireland Georgina, Whitaker Heather, Ladhani Shamez N, Baawuah Frances, Subbarao Sathyvani, Linley Ezra, Warrener Lenesha, O’Brien Michelle, Whillock Corinne, Martin Oliver, Moss Paul, Ramsay Mary E, Amirthalingam Gayatri, Brown Kevin E. Serological responses to COVID-19 Comirnaty booster vaccine, London, United Kingdom, September to December 2021. Euro Surveill. 2022;27(1):pii=2101114. DOI: https://doi.org/10.2807/1560-7917.ES.2022.27.1.2101114

PY - 2022/1/6

Y1 - 2022/1/6

N2 - Serum samples were collected pre- and post-booster vaccination with Comirnaty in 626 participants (aged ≥50 years) who had received two Comirnaty doses<30 days apart, two Comirnaty doses≥30 days apart or two Vaxzevria doses≥30 days apart. Irrespective of primary vaccine type or schedule, spike antibody GMTs peaked 2–4 weeks after second dose, fell significantly≤38 weeks later and rose above primary immunisation GMTs 2–4 weeks post-booster. Higher post-booster responses were observed with a longer interval between primary immunisation and boosting.

AB - Serum samples were collected pre- and post-booster vaccination with Comirnaty in 626 participants (aged ≥50 years) who had received two Comirnaty doses<30 days apart, two Comirnaty doses≥30 days apart or two Vaxzevria doses≥30 days apart. Irrespective of primary vaccine type or schedule, spike antibody GMTs peaked 2–4 weeks after second dose, fell significantly≤38 weeks later and rose above primary immunisation GMTs 2–4 weeks post-booster. Higher post-booster responses were observed with a longer interval between primary immunisation and boosting.

UR - http://www.scopus.com/inward/record.url?scp=85123271555&partnerID=8YFLogxK

U2 - 10.2807/1560-7917.ES.2022.27.1.2101114

DO - 10.2807/1560-7917.ES.2022.27.1.2101114

M3 - Article

C2 - 34991777

AN - SCOPUS:85123271555

SN - 1025-496X

VL - 27

JO - Eurosurveillance

JF - Eurosurveillance

IS - 1

M1 - 2101114

ER -

Serological responses to COVID-19 Comirnaty booster vaccine, London, United Kingdom, September to December 2021

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this